The core activity of AMYRA Biotech is the development and research of Brush Border Enzyme Supplementation Technology (BBEST), particularly for the treatment of general health and nutrition issues, food intolerances and gastrointestinal diseases through the supplementation of enzymes found in the small intestine mucosa.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Technology for supplementing brush border enzymes in the small intestine, to support digestion, nutrient absorption and gastrointestinal health; includes consumer healthcare and pharmaceutical applications.
AMYNOPEP
Enzyme combination for rapid release in the small intestine, for breaking down hard-to-digest protein fragments including gluten, and to support digestion and amino acid uptake.
Consumer healthcare products for digestion
Products for general health and nutrition as well as for food intolerances, developed to support intestinal digestive function within the BBEST pipeline.
Prescription medicines for digestion
Pharmaceutical products for intestinal digestion in gastrointestinal diseases, developed within the BBEST pipeline for clinical and preclinical applications.
Knowledge
No knowledge articles yet
Once Amyra Biotech AG has claimed this profile, we'll publish editorial articles and case studies here together.